Clinical Trials最新文献

{"title":"Commentary on Wittes et al: Aspirin for primary prevention of CV events - Rationally robust? Statistically significant? Clinically convincing?","authors":"John Gf Cleland, Danyaal Anzar","doi":"10.1177/17407745251324865","DOIUrl":"https://doi.org/10.1177/17407745251324865","url":null,"abstract":"","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"17407745251324865"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing institutional responsibility in scientific misconduct: A case study of enoximone research by Joachim Boldt.","authors":"Christian J Wiedermann","doi":"10.1177/17407745241297162","DOIUrl":"10.1177/17407745241297162","url":null,"abstract":"<p><strong>Background: </strong>Enoximone, a phosphodiesterase III inhibitor, was approved in Germany in 1989 and initially proposed for heart failure and perioperative cardiac conditions. The research of Joachim Boldt and his supervisor Gunter Hempelmann came under scrutiny after investigations revealed systematic scientific misconduct leading to numerous retractions. Therefore, early enoximone studies by Boldt and Hempelmann from 1988 to 1991 were reviewed.</p><p><strong>Methods: </strong>PubMed-listed publications and dissertations on enoximone from the Justus-Liebig-University of Giessen were analyzed for study design, participant demographics, methods, and outcomes. The data were screened for duplications and inconsistencies.</p><p><strong>Results: </strong>Of seven randomized controlled trial articles identified, two were retracted. Five of the non-retracted articles reported similarly designed studies and included similar patient cohorts. The analysis revealed overlap in patient demographics and reported outcomes and inconsistencies in cardiac index values between trials, suggesting data duplication and manipulation. Several other articles have been retracted. The analysis results of misconduct and co-authorship of retracted studies during Boldt's late formative years indicate inadequate mentorship. The university's slow response in supporting the retraction of publications involving scientific misconduct indicates systemic oversight problems.</p><p><strong>Conclusion: </strong>All five publications analyzed remained active and warrant retraction to maintain the integrity of the scientific record. This analysis highlights the need for improved institutional supervision. The current guidelines of the Committee on Publication Ethics for retraction are inadequate for large-scale scientific misconduct. Comprehensive ethics training, regular audits, and transparent reporting are essential to ensure the credibility of published research.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"239-247"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the presence of surgical learning in the Timing of Primary Surgery for cleft palate randomised trial.","authors":"Elizabeth J Conroy, Jane M Blazeby, Girvan Burnside, Jonathan A Cook, Carrol Gamble","doi":"10.1177/17407745241302488","DOIUrl":"10.1177/17407745241302488","url":null,"abstract":"<p><p>Background/aimsWhen conducting a randomised controlled trial in surgery, it is important to consider surgical learning, where surgeons' familiarity with one, or both, of the interventions increases during the trial. If present, learning may compromise trial validity. We demonstrate a statistical investigation into surgical learning within a trial of cleft palate repair.MethodsThe Timing of Primary Surgery compared primary surgery, using the Sommerlad technique, for cleft palate repair delivered at 6 or 12 months of age. Participating surgeons had varying levels of experience with the intervention and in repair across the age groups. Trial design aimed to reduce the surgical learning via pre-trial surgical technique training and balancing the randomisation process by surgeon. We explore residual learning effects by applying visual methods and statistical models to a surgical outcome (fistula formation) and a process indicator (operation time).ResultsNotably, 26 surgeons operated on 521 infants. As the trial progressed, operation time reduced for surgeons with no pre-trial Sommerlad experience (n = 2), before plateauing at 30 operations, whereas it remained stable for those with prior experience. Fistula rates remained stable regardless of technique experience. Pre-trial age for primary surgery experience had no impact on either measures.ConclusionManaging learning effects through design was not fully achieved but balanced between trial arms, and residual effects were minimal. This investigation explores the presence of learning, within a randomised controlled trial that may be valuable for future trials. We recommend such investigations are undertaken to aid trial interpretation and generalisability, and determine success of trial design measures.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"200-208"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986075/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142945660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consent to recontact for future research using linked primary healthcare data: Outcomes and general practice perceptions from the ATHENA COVID-19 study.","authors":"Kim Greaves, Amanda King, Zoltan Bourne, Jennifer Welsh, Mark Morgan, Maria Ximena Tolosa, Trisha Johnston, Carissa Bonner, Tony Stanton, Rosemary Korda","doi":"10.1177/17407745241304094","DOIUrl":"https://doi.org/10.1177/17407745241304094","url":null,"abstract":"<p><strong>Background: </strong>The ATHENA COVID-19 study was set up to recruit a cohort of patients with linked health information willing to be recontacted in future to participate in clinical trials and also to investigate the outcomes of people with COVID-19 in Queensland, Australia, using consent. This report describes how patients were recruited, their primary care data extracted, proportions consenting, outcomes of using the recontact method to recruit to a study, and experiences interacting with general practices requested to release the primary care data.</p><p><strong>Methods: </strong>Patients diagnosed with COVID-19 from 1 January 2020 to 31 December 2020 were systematically approached to gain consent to have their primary healthcare data extracted from their general practice into a Queensland Health database and linked to other datasets for ethically approved research. Patients were also asked to consent to allow future recontact to discuss participation in clinical trials and other research studies. Patients who consented to recontact were later approached to recruit to a long-COVID study. Patients' general practices were contacted to export the patient files. All patient and general practice interactions were recorded. Outcome measures were proportions of patients consenting to data extraction and research, permission to recontact, proportions of general practices agreeing to participate. A thematic analysis was conducted to assess attitudes regarding export of healthcare data, and the proportions consenting to participate in the long-COVID study were also reported.</p><p><strong>Results: </strong>Of 1212 patients with COVID-19, contact details were available for 1155; 995 (86%) were successfully approached, and 842 (85%) reached a consent decision. Of those who reached a decision, 581 (69%), 615 (73%) and 629 (75%) patients consented to data extraction, recontact, and both, respectively. In all, 382 general practices were contacted, of whom 347 (91%) had an electronic medical record compatible for file export. Of these, 335 (88%) practices agreed to participate, and 12 (3%) declined. In total, 526 patient files were exported. The majority of general practices supported the study and accepted electronic patient consent as legitimate. For the long-COVID study, 376 (90%) of those patients recontacted agreed to have their contact details passed onto the long-COVID study team and 192 (53%) consented to take part in their study.</p><p><strong>Conclusion: </strong>This report describes how primary care data were successfully extracted using consent, and that the majority of patients approached gave permission for their healthcare information to be used for research and be recontacted. The consent-to-recontact concept demonstrated its effectiveness to recruit to new research studies. The majority of general practices were willing to export identifiable patient healthcare data for linkage provided consent had been obtained.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":"22 2","pages":"188-199"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143976742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The state of individual participant data sharing for the highest-revenue medicines.","authors":"Natansh D Modi, Lee X Li, Jessica M Logan, Michael D Wiese, Ahmad Y Abuhelwa, Ross A McKinnon, Andrew Rowland, Michael J Sorich, Ashley M Hopkins","doi":"10.1177/17407745241286147","DOIUrl":"10.1177/17407745241286147","url":null,"abstract":"<p><p>BackgroundAmid growing emphasis from pharmaceutical companies, advocacy groups, and regulatory bodies for sharing of individual participant data, recent audits reveal limited sharing, particularly for high-revenue medicines. Therefore, this study aimed to assess the individual participant data-sharing eligibility of clinical trials supporting the Food and Drug Administration approval of the top 30 highest-revenue medicines for 2021.MethodsA cross-sectional analysis was conducted on 316 clinical trials supporting approval of the top 30 revenue-generating medicines of 2021. The study assessed whether these trials were eligible for individual participant data sharing, defined as being publicly listed on a data-sharing platform or confirmed by the trial sponsors as in scope for independent researcher individual participant data investigations. Information was gathered from various sources including ClinicalTrials.gov, the European Union Clinical Trials Register, and PubMed. Key factors such as the trial phase, completion dates, and the nature of the data-sharing process were also examined.ResultsOf the 316 trials, 201 (64%) were confirmed eligible for sharing, meaning they were either publicly listed on a data-sharing platform or confirmed by the trial sponsors as in scope for independent researcher individual participant data investigations. A total of 102 (32%) were confirmed ineligible, and for 13 (4%), the sponsor indicated that a full research proposal would be required to determine eligibility. The analysis also revealed a higher rate of individual participant data sharing among companies that utilized independent platforms, such as Vivli, for managing their individual participant data-sharing process. Trials not marked as completed had significantly lower eligibility for individual participant data sharing.ConclusionThis study highlights that a substantial portion of trials for top revenue-generating medicines are eligible for individual participant data sharing. However, challenges persist, particularly for trials that are marked as ongoing and for trials where the sharing processes are managed internally by pharmaceutical companies. Data-sharing rates could be improved by adopting open-access individual participant data-sharing models or using independent platforms. Standardizing policies to facilitate immediate individual participant data availability for approved medicines is necessary.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"170-177"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on Toerper et al: A step in the right direction for learning health systems.","authors":"Mark J Pletcher","doi":"10.1177/17407745241302023","DOIUrl":"https://doi.org/10.1177/17407745241302023","url":null,"abstract":"","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":"22 2","pages":"152-154"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992430/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NHS-Galleri trial: Enriched enrolment approaches and sociodemographic characteristics of enrolled participants.","authors":"Charles Swanton, Velicia Bachtiar, Chris Mathews, Adam R Brentnall, Ian Lowenhoff, Jo Waller, Martine Bomb, Sean McPhail, Heather Pinches, Rebecca Smittenaar, Sara Hiom, Richard D Neal, Peter Sasieni","doi":"10.1177/17407745241302477","DOIUrl":"10.1177/17407745241302477","url":null,"abstract":"<p><strong>Background/aims: </strong>Certain sociodemographic groups are routinely underrepresented in clinical trials, limiting generalisability. Here, we describe the extent to which enriched enrolment approaches yielded a diverse trial population enriched for older age in a randomised controlled trial of a blood-based multi-cancer early detection test (NCT05611632).</p><p><strong>Methods: </strong>Participants aged 50-77 years were recruited from eight Cancer Alliance regions in England. Most were identified and invited from centralised health service lists; a dynamic invitation algorithm was used to target those in older and more deprived groups. Others were invited by their general practice surgery (GP-based Participant Identification Centres in selected regions); towards the end of recruitment, specifically Asian and Black individuals were invited via this route, as part of a concerted effort to encourage enrolment among these individuals. Some participants self-referred, often following engagement activities involving community organisations. Enrolment took place in 11 mobile clinics at 151 locations that were generally more socioeconomically deprived and ethnically diverse than the England average. We reduced logistical barriers to trial participation by offering language interpretation and translation and disabled access measures. After enrolment, we examined (1) sociodemographic distribution of participants versus England and Cancer Alliance populations, and (2) number needed to invite (NNI; the number of invitations sent to enrol one participant) by age, sex, index of multiple deprivation (IMD) and ethnicity, and GP surgery-level bowel screening participation.</p><p><strong>Results: </strong>Approximately 1.5 million individuals were invited and 142,924 enrolled (98% via centralised health service lists/invitation algorithm) in 10.5 months. The enrolled population was older and more deprived than the England population aged 50-77 years (73.3% vs 56.8% aged 60-77 years; 42.3% vs 35.3% in IMD groups 1-2). Ethnic diversity was lower in the trial than the England population (1.4% vs 2.8% Black; 3.3% vs 5.3% Asian). NNI was highest in Black (32.8), Asian (28.2) and most-deprived (21.5) groups, and lowest in mixed ethnicity (8.1) and least-deprived (4.6) groups.</p><p><strong>Conclusions: </strong>Enrolment approaches used in the NHS-Galleri trial enabled recruitment of an older, socioeconomically diverse participant population relatively rapidly. Compared with the England and Cancer Alliance populations, the enrolled population was enriched for those in older age and more deprived groups. Better ethnicity data availability in central health service records could enable better invitation targeting to further enhance ethnically diverse recruitment. Future research should evaluate approaches used to facilitate recruitment from underrepresented groups in clinical trials.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"227-238"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143036914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using non-inferiority test of proportions in design of randomized non-inferiority trials with time-to-event endpoint with a focus on low-event-rate setting.","authors":"Lingyun Ji, Todd A Alonzo","doi":"10.1177/17407745241284786","DOIUrl":"10.1177/17407745241284786","url":null,"abstract":"<p><p>Background/aimsFor cancers with low incidence, low event rates, and a time-to-event endpoint, a randomized non-inferiority trial designed based on the logrank test can require a large sample size with significantly prolonged enrollment duration, making such a non-inferiority trial not feasible. This article evaluates a design based on a non-inferiority test of proportions, compares its required sample size to the non-inferiority logrank test, assesses whether there are scenarios for which a non-inferiority test of proportions can be more efficient, and provides guidelines in usage of a non-inferiority test of proportions.MethodsThis article describes the sample size calculation for a randomized non-inferiority trial based on a non-inferiority logrank test or a non-inferiority test of proportions. The sample size required by the two design methods are compared for a wide range of scenarios, varying the underlying Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.ResultsOur results showed that there are scenarios for which the non-inferiority test of proportions can have significantly reduced sample size. Specifically, the non-inferiority test of proportions can be considered for cancers with more than 80% long-term survival rate. We provide guidance in choice of this design approach based on parameters of the Weibull survival functions, the non-inferiority margin, and loss to follow-up rate.ConclusionFor cancers with low incidence and low event rates, a non-inferiority trial based on the logrank test is not feasible due to its large required sample size and prolonged enrollment duration. The use of a non-inferiority test of proportions can make a randomized non-inferiority Phase III trial feasible.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":" ","pages":"131-141"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11991896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estimating treatment effects from a randomized controlled trial with mid-trial design changes.","authors":"Sudeshna Paul, Jaeun Choi, Mi-Kyung Song","doi":"10.1177/17407745241304120","DOIUrl":"https://doi.org/10.1177/17407745241304120","url":null,"abstract":"<p><p>BackgroundIn randomized controlled trials (RCTs), unplanned design modifications due to unexpected circumstances are seldom reported. Naively lumping data from pre- and post-design changes to estimate the size of the treatment effect, as planned in the original study, can introduce systematic bias and limit interpretability of the trial findings. There has been limited discussion on how to estimate the treatment effect when an RCT undergoes major design changes during the trial. Using our recently completed RCT, which underwent multiple design changes, as an example, we examined the statistical implications of design changes on the treatment effect estimates.MethodsOur example RCT aimed to test an advance care planning intervention targeting dementia patients and their surrogate decision-makers compared to usual care. The original trial underwent two major mid-trial design changes resulting in three smaller studies. The changes included altering the number of study arms and adding new recruitment sites, thus perturbing the initial statistical assumptions. We used a simulation study to mimic these design modifications in our RCT, generate independent patient-level data and evaluate naïve lumping of data, a two-stage fixed-effect and random-effect meta-analysis model to obtain an average effect size estimate from all studies. Standardized mean-difference and odds-ratio estimates at post-intervention were used as effect sizes for continuous and binary outcomes, respectively. The performance of the estimates from different methods were compared by studying their statistical properties (e.g. bias, mean squared error, and coverage probability of 95% confidence intervals).ResultsWhen between-design heterogeneity is negligible, the fixed- and random-effect meta-analysis models yielded accurate and precise effect-size estimates for both continuous and binary data. As between-design heterogeneity increased, the estimates from random meta-analysis methods indicated less bias and higher coverage probability compared to the naïve and fixed-effect methods, however the mean squared error was higher indicating greater uncertainty arising from a small number of studies. The between-study heterogeneity parameter was not precisely estimable due to fewer studies. With increasing sample sizes within each study, the effect-size estimates showed improved precision and statistical power.ConclusionsWhen a trial undergoes unplanned major design changes, the statistical approach to estimate the treatment effect needs to be determined carefully. Naïve lumping of data across designs is not appropriate even when the overall goal of the trial remains unchanged. Understanding the implications of the different aspects of design changes and accounting for them in the analysis of the data are essential for internal validity and reporting of the trial findings. Importantly, investigators must disclose the design changes clearly in their study reports.</p>","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":"22 2","pages":"209-219"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11996067/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Epic^® to facilitate high-quality randomization of emergency department-based pragmatic clinical trials.","authors":"Matthew F Toerper, Jason Haukoos, Emily Hopkins, Sarah E Rowan, Michael S Lyons, James W Galbraith, Yu-Hsiang Hsieh, Douglas Ae White, Scott Levin, Jeremiah Hinson, Richard E Rothman","doi":"10.1177/17407745241301998","DOIUrl":"https://doi.org/10.1177/17407745241301998","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Pragmatic clinical trials are critical to determine the real-world effectiveness of interventions. Emergency departments serve as key clinical sites for such trials because they provide care to large numbers of patients at the earliest point in their hospital encounter. However, few methods that facilitate efficient emergency department-based pragmatic trials have been described. Our objective was to design and embed randomization schemes directly into the electronic health record to facilitate enrollment of emergency department patients by clinical staff 24 h per day, while maintaining concealed and balanced allocation.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;We designed two multi-center pragmatic trials screening for human immunodeficiency virus (HIV TESTED trial) and hepatitis C virus (DETECT Hep C trial). HIV TESTED included four sites, three arms, and compared two forms of risk-assessed (targeted) to non-risk-assessed (nontargeted) screening for human immunodeficiency virus; DETECT Hep C included three sites, two arms, and compared targeted to nontargeted screening for hepatitis C virus. Participant entry occurred during a patient's emergency department visit in conjunction with standard emergency department care. Patient-visit level randomization schemes were designed in each electronic health record system using Epic&lt;sup&gt;®&lt;/sup&gt; (Epic Systems, Verona, WI; two sites for HIV TESTED; all three sites for DETECT Hep C). Randomization and all forms of screening were fully embedded and integrated in the electronic health record and administered by nurses as part of routine care. Absolute differences and chi-square testing were used to evaluate randomness of study arms and to compare baseline characteristics. Time-motion methods were also used to assess the time of screening and randomization by nurses.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;During 61 cumulative enrollment months, 365,462 patient visits occurred. After excluding 184,023 visits by designed electronic health record logic or manual nurse input due to age, previously known human immunodeficiency virus or hepatitis C virus, high acuity or altered mental status, 181,439 patient visits were randomized to one of the interventions. Absolute differences between targeted and nontargeted arms differed by 0.2% and 0.4% (HIV TESTED), and 0.1% (DETECT Hep C), and median absolute differences across all baseline characteristics (i.e. age, sex, race, ethnicity, language, payor, arrival mode, and acuity) between arms were 0.02% (range: -0.7% to +0.5%) and -0.07% (range: -0.3% to +0.7%), and -0.02% (range: -0.7% to +0.7%), respectively. Median time required for nurses to execute randomization ranged from 16 to 67 s, depending on the arm.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Integration of blinded randomization schemes into electronic health record systems resulted in high-volume balanced enrollment of participants 24 h per day while maintaining concealed allocation. Use of this technol","PeriodicalId":10685,"journal":{"name":"Clinical Trials","volume":"22 2","pages":"142-151"},"PeriodicalIF":2.2,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}